安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Universally Implantable Regenerative Human Tissues - Humacyte Global, Inc.
Humacyte ® is pioneering a platform that enables the investigation, development, and manufacture of bioengineered human tissues and organs that are designed to be universally implantable, off-the-shelf, and regenerative, with the goal of treating a wide variety of diseases, injuries, and chronic conditions
- Pipeline - Humacyte Global, Inc.
Our Breakthroughs in science and technology aim to turn once-futuristic ideas into reality through the development of bioengineered regenerative human tissues Pioneering research in three revolutionary platforms – Acellular Tissue Engineered Vessels, Advanced Organ Systems, and Advanced Tissue Constructs – we are investigating regenerative approaches for a wide range of clinical needs
- Leadership - Humacyte Global, Inc.
Dr Niklason is the founder of Humacyte and has served as its President and CEO since 2020 She served Humacyte as a senior scientist from 2004 through 2020 Dr
- Our Story - Humacyte Global, Inc.
“When Humacyte was first founded, many people thought our goal of creating an off-the-shelf human-derived vessel was the stuff of dreams The twenty years of dedication that led to this point brought forth a new reality
- Bioengineering Process - Humacyte Global, Inc.
Our first-in-class bioengineering technology and manufacturing process aims to transform human cells into universally implantable, regenerative tissues and advanced organ systems, for use in the treatment of injury and disease, across a wide range of clinical needs
- Humacyte Announces Commercial Launch of Symvess™ (acellular tissue . . .
Humacyte’s initial product candidates, a portfolio of acellular tissue engineered vessels (ATEVs), are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease
- Acellular Tissue Engineered Vessels - Humacyte Global, Inc.
Humacyte’s investigational ATEV is designed to provide an alternative to current standards of care for hemodialysis patients with End-Stage Renal Disease (ESRD) The Unmet Need Development Status Infection is the leading cause of morbidity and mortality in hemodialysis patients
- Humacyte First Quarter 2024 Financial Results and Business Update
DURHAM, N C , May 10, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced financial results for the first quarter ended March 31, 2024 and highlighted recent accomplishments advancing the
|
|
|